Alchemab Therapeutics, a biotech company developing novel products for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, today announces the completion of a £60 million ($82 million) Series A financing round.
Who to call at Alchemab Therapeutics, and when
A new round usually means Alchemab Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Alchemab Therapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Alchemab Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Alchemab Therapeutics. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Alchemab Therapeutics
Location
London, England, United Kingdom
About
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development.
Alchemab takes an unbiased and function-first approach using three complementary processes and cutting-edge technologies to identify naturally protective antibodies.
Alchemab’s engine is enabled through collaborations with patient representative groups and biobanks around the world with whom we partner to further our understanding of disease.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Alchemab Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
LondonBiotechnologyHealth CareTherapeuticsPharmaceutical